中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

2273 records (took 0.03 seconds)

    Hydroxylansoprazole methods
    91.
    发明申请
    Hydroxylansoprazole methods 审中-公开
    羟基索非唑方法

    公开(公告)号：US20020099079A1

    公开(公告)日：2002-07-25

    申请号：US10046464

    申请日：2001-10-19

    Applicant: SEPRACOR INC.

    Inventor： William E. Yelle

    IPC: A61K031/4439

    CPC classification number: A61K31/4439

    Abstract: Methods and compositions are disclosed utilizing hydroxylansoprazole for the treatment of ulcers in humans. Hydroxylansoprazole exhibits a lessened liability toward drug-drug interactions than lansoprazole and a more predictable dosing regimen than lansoprazole. Hydroxylansoprazole is also useful for the treatment of gastroesophageal reflux and other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了利用羟基索非唑来治疗人类溃疡的方法和组合物。 羟考兰唑与兰索拉唑相比显着降低药物相互作用的责任，比兰索拉唑更可预测的给药方案。 羟基索非唑还可用于治疗胃食管反流和其他与胃分泌过多相关的病症，例如Zollinger-Ellison综合征。

    Methods and compositions using norastemizole in combination with leukotriene inhibitors
    92.
    发明申请
    Methods and compositions using norastemizole in combination with leukotriene inhibitors 审中-公开
    使用诺尔阿司咪唑联合白三烯抑制剂的方法和组合物

    公开(公告)号：US20020086854A1

    公开(公告)日：2002-07-04

    申请号：US10084250

    申请日：2002-02-28

    Applicant: Sepracor, Inc.

    Inventor： Paul D. Rubin

    IPC: A61K031/454 ,  A61K031/415

    CPC classification number: A61K45/06 ,  A61K31/445 ,  Y10S514/826

    Abstract: Methods and pharmaceutical compositions employing norastemizole and a leukotriene inhibitor for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof. Also included are methods and compositions employing norastemizole and a decongestant for the treatment or prevention of inflammation or allergic disorders, such as asthma or the symptoms thereof.

    Abstract translation: 使用诺尔阿司咪唑和白三烯抑制剂用于治疗或预防炎症或过敏性疾病如哮喘或其症状的方法和药物组合物。 还包括使用诺尔阿司咪唑和减充血剂用于治疗或预防炎症或过敏性疾病如哮喘或其症状的方法和组合物。

    Methods and compositions for treating gastric disorders using optically pure (+)-pantoprazole
    95.
    发明申请
    Methods and compositions for treating gastric disorders using optically pure (+)-pantoprazole 审中-公开
    使用光学纯（+） - 泮托拉唑治疗胃疾病的方法和组合物

    公开(公告)号：US20020019420A1

    公开(公告)日：2002-02-14

    申请号：US09948983

    申请日：2001-09-07

    Applicant: Sepracor Inc.

    Inventor： Nancy M. Gray

    IPC: A61K031/4439

    CPC classification number: A61K31/44

    Abstract: Methods and compositions are disclosed utilizing optically pure (null) pantoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of pantoprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Pantoprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了使用光学纯的（+）泮托拉唑用于治疗人体溃疡的方法和组合物，同时显着降低与泮托拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）泮托拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Optically pure (-) amlodipine compositions
    96.
    发明申请
    Optically pure (-) amlodipine compositions 失效
    光学纯（ - ）氨氯地平组合物

    公开(公告)号：US20020010200A1

    公开(公告)日：2002-01-24

    申请号：US09915573

    申请日：2001-07-27

    Applicant: Sepracor Inc.

    Inventor： James W. Young

    IPC: A61K031/44

    CPC classification number: A61K31/44 ,  Y10S514/866 ,  Y10S514/929

    Abstract: Methods and compositions are disclosed utilizing the optically pure (null) isomer of amlodipine. This compound is a potent drug for the treatment of hypertension while avoiding the concomitant liability of adverse effects associated with the racemic mixture of amlodipine. The (null) isomer of amlodipine is also useful for the treatment of angina and such other conditions as may be related to the activity of (null) amlodipine as a calcium channel antagonist such as cerebral ischemia, cerebral disorders, arrhythmias, cardiac hypertrophy, coronary vasospasm, myocardial infarction, renal impairment and acute renal failure, without the concomitant liability of adverse effects associated with the racemic mixture of amlodipine.

    Abstract translation: 公开利用氨氯地平的光学纯（ - ）异构体的方法和组合物。 该化合物是治疗高血压的有效药物，同时避免与氨氯地平外消旋混合物相关的副作用的伴随责任。 氨氯地平的（ - ）异构体也可用于治疗心绞痛和其他可能与（ - ）氨氯地平作为钙通道拮抗剂如脑缺血，脑障碍，心律失常，心脏肥大，冠状动脉 血管痉挛，心肌梗塞，肾功能衰竭和急性肾功能衰竭，无与氨氯地平外消旋混合物相关的副作用的伴随责任。

    COMPOSITIONS FOR TREATING ALERGIC AND OTHER DISORDERS USING NORASTEMIZOLE IN COMBINATION WITH OTHER ACTIVE INGREDIENTS
    97.
    发明申请
    COMPOSITIONS FOR TREATING ALERGIC AND OTHER DISORDERS USING NORASTEMIZOLE IN COMBINATION WITH OTHER ACTIVE INGREDIENTS 失效
    用于治疗与其他活性成分组合使用诺沙匹的ALERGIC和其他疾病的组合物

    公开(公告)号：US20010053787A1

    公开(公告)日：2001-12-20

    申请号：US09835149

    申请日：2001-04-16

    Applicant: Sepracor Inc.

    Inventor： Raymond L. Woosley ,  A. K. Gunnar Aberg

    IPC: A61K031/445

    CPC classification number: A61K31/454 ,  A61K31/445 ,  A61K2300/00

    Abstract: Methods and compositions are disclosed utilizing metabolic derivatives of astemizole for the treatment of allergic disorders while avoiding the concomitant liability of adverse effects associated with the astemizole. The metabolic derivatives of astemizole are also useful for the treatment of retinopathy and other small vessel disorders associated with diabetes mellitus and such other conditions as may be related to the antihistamine activity of astemizole. For example, the metabolic derivatives of astemizole are useful for the treatment of asthma, motion sickness, and vertigo, without the concomitant liability of adverse effects associated with astemizole. Furthermore, the metabolic derivatives of astemizole, in combination with non-steroidal anti-inflammatory agents or other non-narcotic analgesics, or in combination with a decongestant, cough suppressant/antitussive or expectorant, are useful for the treatment of cough, cold, cold-like, and/or flu symptoms and the discomfort, headache, pain, fever, and general malaise associated therewith, without the concomitant liability of adverse effects associated with astemizole.

    Abstract translation: 公开了利用阿司咪唑的代谢衍生物治疗过敏性疾病的方法和组合物，同时避免与阿司咪唑相关的副作用的伴随的责任。 阿司咪唑的代谢衍生物也可用于治疗与糖尿病相关的视网膜病变和其它小血管障碍以及可能与阿司咪唑的抗组织胺活性相关的其它病症。 例如，阿司咪唑的代谢衍生物可用于治疗哮喘，晕车和眩晕，而不伴随与阿司咪唑有关的不良反应。 此外，阿司咪唑的代谢衍生物与非甾体抗炎剂或其他非麻醉止痛剂组合，或与减充血剂，止咳剂/镇咳药或祛痰剂组合可用于治疗咳嗽，感冒，感冒 类似，和/或流感症状以及与之相关的不适，头痛，疼痛，发烧和全身不适，而不伴随与阿司咪唑有关的不良反应。

    Methods of treating and preventing narcolepsy using enantiomerically pure (s)-didesmethylsibutramine
    98.
    发明申请
    Methods of treating and preventing narcolepsy using enantiomerically pure (s)-didesmethylsibutramine 审中-公开
    使用对映异构纯的甲基西布曲明治疗和预防发作性睡病的方法

    公开(公告)号：US20040116534A1

    公开(公告)日：2004-06-17

    申请号：US10717653

    申请日：2003-11-21

    Applicant: Sepracor, Inc.

    Inventor： Thomas P. Jerussi

    IPC: A61K031/519 ,  A61K031/137

    CPC classification number: A61K31/50 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K31/40 ,  A61K31/415 ,  A61K31/44 ,  A61K31/475 ,  A61K31/495 ,  A61K31/505 ,  A61K31/52 ,  A61K45/06 ,  A61K2300/00

    Abstract: Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

    Abstract translation: 公开了用于治疗和预防疾病和病症的方法，例如但不限于：进食障碍; 体重增加; 肥胖; 过敏性肠综合征; 强迫症; 血小板粘附; 呼吸暂停 情感障碍，如注意力缺陷障碍，抑郁症和焦虑症; 男性和女性性功能障碍; 不安腿综合征 骨关节炎 药物滥用，包括尼古丁和可卡因成瘾; 发作性睡病 疼痛如神经性疼痛，糖尿病性神经病和慢性疼痛; 偏头痛 脑功能障碍; 慢性疾病如经前期综合征; 和失禁。 还公开了药物组合物和剂型，其包含外消旋或光学纯的西布曲明代谢物和任选的另外的药理活性化合物。

    Methods of preparing didesmethylsibutramine and other sibutramine derivatives
    100.
    发明申请
    Methods of preparing didesmethylsibutramine and other sibutramine derivatives 有权
    二甲基西布曲明和其他西布曲明衍生物的制备方法

    公开(公告)号：US20040087660A1

    公开(公告)日：2004-05-06

    申请号：US10643941

    申请日：2003-08-20

    Applicant: Sepracor Inc.

    Inventor： Chris Hugh Senanayake ,  Zhengxu Han ,  Dhileepkumar Krishnamurthy ,  Derek Pflum

    IPC: A61K031/137

    CPC classification number: C07C209/60 ,  C07C313/06 ,  C07C2601/04 ,  C07C211/29

    Abstract: This invention encompasses novel methods of preparing sibutramine and sibutramine derivatives, and stereomerically pure sibutramine derivatives in particular. Examples of sibutramine derivatives include, but are not limited to, sibutramine metabolites such as desmethylsibutramine and didesmethylsibutramine. The invention further encompasses novel compounds useful in the synthesis of sibutramine derivatives.

    Abstract translation: 本发明包括制备西布曲明和西布曲明衍生物的新方法，特别是立体异构纯的西布曲明衍生物。 西布曲明衍生物的实例包括但不限于西布曲明代谢物如脱甲基西布曲明和二甲基西布曲明。 本发明还包括可用于合成西布曲明衍生物的新化合物。

Patent Agency Ranking